Cygnus Technologies, TriLink BioTechnologies, both part of Maravai LifeSciences, have collaborated to launch Cygnus’ AccuRes Host Cell DNA Quantification Kits. Together, the companies have leveraged state-of-the-art technologies and reagents to develop an assay with unparalleled sensitivity and specificity to help produce safer, more stable biotherapeutics that surpass regulatory standards.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Biotech Alert: Searches spiking for these stocks today
- Stifel has ‘mixed feelings’ about Repligen approaching Maravai
- Repligen drops 9%, Maravai rallies 17% following Reuters report
- Repligen approached Maravai with acquisition offer, Reuters reports
- Repligen approached Maravai with takeover offer, Reuters reports